Robert Cannon, M.D., the surgical director of the UAB Liver Transplant Program, was recently featured on UAB's MedCast Podcast. 

In the episode, Cannon discusses the diagnosis and treatment options available for liver cancer patients. Through the conversation, Cannon focuses on hepatocellular carcinoma (HCC), which is the most common type of liver cancer. 

About Hepatocellular Carcinoma

In the podcast, Cannon explains that Hepatocellular Carcinoma (HCC) is the fifth most common type of cancer worldwide and the third most common cause of death. He mentions that this disease can be caused by various factors leading to chronic liver disease. Fatty liver disease, which can be caused by obesity, high cholesterol, and diabetes, is the most rapidly growing cause of HCC in the United States. 

Cannon is not only responsible for treating HCC but also treats many subtypes of primary liver malignancies. He discusses that UAB has a wide range of treatments available and how physicians aim to use the best curative strategies possible and therapies to increase a patient's quality of life. 

Why should patients choose UAB?

A pioneer in patient care, UAB has introduced a new approach to treatment by utilizing an advanced, integrated center for liver cancer. By having a single treatment facility, patients can see multiple specialists regarding their treatment plan in one visit, eliminating the need for the patient to make multiple visits to see each care provider individually. 

"The Multi-Disciplinary Hepatocellular Carcinoma Clinic will provide access to the full spectrum of treatment options for HCC, including surgery, systemic therapy, radiation, and interventional radiology procedures. Patients can expect to receive a personalized treatment plan that meets their needs," says Cannon. 

To listen to the full episode, visit the UAB MedCast website.